[177Lu]Lu-PSMA-617与多西他赛在化疗中的比较——转移性Castion-Ristant前列腺癌癌症:2期随机对照试验的最终生存分析。

IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Journal of Nuclear Medicine Pub Date : 2023-11-01 Epub Date: 2023-09-14 DOI:10.2967/jnumed.123.266141
Swayamjeet Satapathy, Bhagwant Rai Mittal, Ashwani Sood, Chandan Krushna Das, Ravimohan Suryanarayan Mavuduru, Shikha Goyal, Jaya Shukla, Shrawan Kumar Singh
{"title":"[177Lu]Lu-PSMA-617与多西他赛在化疗中的比较——转移性Castion-Ristant前列腺癌癌症:2期随机对照试验的最终生存分析。","authors":"Swayamjeet Satapathy,&nbsp;Bhagwant Rai Mittal,&nbsp;Ashwani Sood,&nbsp;Chandan Krushna Das,&nbsp;Ravimohan Suryanarayan Mavuduru,&nbsp;Shikha Goyal,&nbsp;Jaya Shukla,&nbsp;Shrawan Kumar Singh","doi":"10.2967/jnumed.123.266141","DOIUrl":null,"url":null,"abstract":"<p><p>The prostate-specific membrane antigen (PSMA) inhibitor [<sup>177</sup>Lu]Lu-PSMA-617 has been previously demonstrated to be noninferior to docetaxel in achieving a biochemical response in chemotherapy-naïve metastatic castration-resistant prostate cancer patients. Here, we report the final analysis of overall survival (OS) for a phase 2 randomized, controlled trial. <b>Methods:</b> Forty chemotherapy-naïve, PSMA-positive metastatic castration-resistant prostate cancer patients were randomly assigned to [<sup>177</sup>Lu]Lu-PSMA-617 (<i>n</i> = 20) or docetaxel (<i>n</i> = 20). Thirty-five patients received treatment per the protocol. Survival analysis was done using Kaplan-Meier curves and the Cox regression model. <b>Results:</b> The mean follow-up duration was 33.4 mo. In intention-to-treat analysis, the median OS for the [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel arms was 15.0 mo (95% CI, 9.5-20.5 mo) and 15.0 mo (95% CI, 8.1-21.9 mo), respectively (<i>P</i> = 0.905). In per-protocol analysis, the median OS was 19.0 mo (95% CI, 12.3-25.7 mo) versus 15.0 mo (95% CI, 8.1-21.9 mo), respectively (<i>P</i> = 0.712). No significant difference in OS was observed between the 2 arms across the analyzed subgroups. <b>Conclusion:</b> Long-term outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 administered earlier in the prechemotherapy setting are comparable to those with docetaxel.</p>","PeriodicalId":16758,"journal":{"name":"Journal of Nuclear Medicine","volume":" ","pages":"1726-1729"},"PeriodicalIF":9.1000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[<sup>177</sup>Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial.\",\"authors\":\"Swayamjeet Satapathy,&nbsp;Bhagwant Rai Mittal,&nbsp;Ashwani Sood,&nbsp;Chandan Krushna Das,&nbsp;Ravimohan Suryanarayan Mavuduru,&nbsp;Shikha Goyal,&nbsp;Jaya Shukla,&nbsp;Shrawan Kumar Singh\",\"doi\":\"10.2967/jnumed.123.266141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The prostate-specific membrane antigen (PSMA) inhibitor [<sup>177</sup>Lu]Lu-PSMA-617 has been previously demonstrated to be noninferior to docetaxel in achieving a biochemical response in chemotherapy-naïve metastatic castration-resistant prostate cancer patients. Here, we report the final analysis of overall survival (OS) for a phase 2 randomized, controlled trial. <b>Methods:</b> Forty chemotherapy-naïve, PSMA-positive metastatic castration-resistant prostate cancer patients were randomly assigned to [<sup>177</sup>Lu]Lu-PSMA-617 (<i>n</i> = 20) or docetaxel (<i>n</i> = 20). Thirty-five patients received treatment per the protocol. Survival analysis was done using Kaplan-Meier curves and the Cox regression model. <b>Results:</b> The mean follow-up duration was 33.4 mo. In intention-to-treat analysis, the median OS for the [<sup>177</sup>Lu]Lu-PSMA-617 and docetaxel arms was 15.0 mo (95% CI, 9.5-20.5 mo) and 15.0 mo (95% CI, 8.1-21.9 mo), respectively (<i>P</i> = 0.905). In per-protocol analysis, the median OS was 19.0 mo (95% CI, 12.3-25.7 mo) versus 15.0 mo (95% CI, 8.1-21.9 mo), respectively (<i>P</i> = 0.712). No significant difference in OS was observed between the 2 arms across the analyzed subgroups. <b>Conclusion:</b> Long-term outcomes with [<sup>177</sup>Lu]Lu-PSMA-617 administered earlier in the prechemotherapy setting are comparable to those with docetaxel.</p>\",\"PeriodicalId\":16758,\"journal\":{\"name\":\"Journal of Nuclear Medicine\",\"volume\":\" \",\"pages\":\"1726-1729\"},\"PeriodicalIF\":9.1000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Nuclear Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2967/jnumed.123.266141\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/14 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2967/jnumed.123.266141","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

前列腺特异性膜抗原(PSMA)抑制剂[177Lu]Lu-PSMA-617先前已被证明在化疗幼稚的转移性去势抵抗性前列腺癌症患者中实现生化反应方面不劣于多烯紫杉醇。在此,我们报告了一项2期随机对照试验的总生存率(OS)的最终分析。方法:将40例化疗幼稚、PSMA阳性转移性去势耐药前列腺癌症患者随机分为[177Lu]Lu-PSMA-617(n=20)或多西他赛(n=20。35名患者按照方案接受了治疗。使用Kaplan-Meier曲线和Cox回归模型进行生存分析。结果:平均随访时间为33.4 在意向治疗分析中,[177Lu]Lu-PSMA-617和多西他赛组的中位OS为15.0 mo(95%置信区间,9.5-20.5 mo)和15.0 mo(95%置信区间,8.1-21.9 mo)(P=0.905)。在按方案分析中,中位OS为19.0 mo(95%置信区间,12.3-25.7 mo)与15.0 mo(95%置信区间,8.1-21.9 mo)(P=0.712)。在所分析的亚组中,两组之间的OS没有观察到显著差异。结论:在化疗前早期给予[177Lu]Lu-PSMA-617的长期疗效与多西他赛相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial.

The prostate-specific membrane antigen (PSMA) inhibitor [177Lu]Lu-PSMA-617 has been previously demonstrated to be noninferior to docetaxel in achieving a biochemical response in chemotherapy-naïve metastatic castration-resistant prostate cancer patients. Here, we report the final analysis of overall survival (OS) for a phase 2 randomized, controlled trial. Methods: Forty chemotherapy-naïve, PSMA-positive metastatic castration-resistant prostate cancer patients were randomly assigned to [177Lu]Lu-PSMA-617 (n = 20) or docetaxel (n = 20). Thirty-five patients received treatment per the protocol. Survival analysis was done using Kaplan-Meier curves and the Cox regression model. Results: The mean follow-up duration was 33.4 mo. In intention-to-treat analysis, the median OS for the [177Lu]Lu-PSMA-617 and docetaxel arms was 15.0 mo (95% CI, 9.5-20.5 mo) and 15.0 mo (95% CI, 8.1-21.9 mo), respectively (P = 0.905). In per-protocol analysis, the median OS was 19.0 mo (95% CI, 12.3-25.7 mo) versus 15.0 mo (95% CI, 8.1-21.9 mo), respectively (P = 0.712). No significant difference in OS was observed between the 2 arms across the analyzed subgroups. Conclusion: Long-term outcomes with [177Lu]Lu-PSMA-617 administered earlier in the prechemotherapy setting are comparable to those with docetaxel.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Nuclear Medicine
Journal of Nuclear Medicine 医学-核医学
CiteScore
13.00
自引率
8.60%
发文量
340
审稿时长
1 months
期刊介绍: The Journal of Nuclear Medicine (JNM), self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), provides readers worldwide with clinical and basic science investigations, continuing education articles, reviews, employment opportunities, and updates on practice and research. In the 2022 Journal Citation Reports (released in June 2023), JNM ranked sixth in impact among 203 medical journals worldwide in the radiology, nuclear medicine, and medical imaging category.
期刊最新文献
C-X-C Motif Chemokine Receptor 4-Directed Scintigraphy of Multiple Myeloma Using [99mTc]Tc-PentixaTec. Debating the Future of Nuclear Medicine: The Greek Experience. Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis Identification of (R)-[18F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development Value of68Ga-FAPI-04 and18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1